Prostatic hypertrophy and cancer treatment review

Vinod C Tawar

Clover Hill Medical Clinic, Canada

Scientific Tracks Abstracts: J Transplant Technol Res

Abstract :

Benign prostatic hypertrophy is of common occurrence in a medical practice, seen in men of advanced age after 50 years. It also leads to obstructive voiding and cancer. Determination of PSA levels have been detection tool in the diagnosis. However, current studies have shown a lack of specificity. The relevance of hypertrophy or cancer in nephrology has been primarily, due to the presence of disease has to be ruled out in male kidney transplant donors. My primary interest in clinical research since 2016 on BPH and cancer has been on searching for safer treatment options e.g. topical formulations consisting 2 of PDE5 inhibitors (Papaverine and Sildenafil). The trials at pilot studies have shown relief from obstructive voiding symptoms, decrease in PSA levels, increased cavernous blood flow, and androgenic effects without a PSA rise. Current evidence has shown a decrease in pre-cancerous PC3 cells with Papaverine. My current research is targeting the assessment of this parameter at monthly intervals of the PDE5 inhibitors. The current literature review from 2015, to date has shown significant evidence supporting the benefit from Papaverine. Some authors have utilized injectable forms; however topical agents have been free of such complication.

Biography :

Vinod C Tawar has completed his Graduate degree at Bombay University in 1964 with major in Chemistry and a minor in Botany with honours. He has completed his postgraduate program in Technology of Pharmaceuticals and Fine Chemicals at Bombay University in 1966. In 1967, he has completed his Master’s degree programme in pharmacology at University of Manitoba, Canada in 1969. In 1970, he has commenced his work as a toxicologist and had established a province wide analytical laboratory in the field till 1981. He has completed his MD degree from Medical School in 1985. He has also completed a 2 years residency, for a licensure as a physician. After a general practice of several years and pharmacology research he was awarded a family physician status in 2008. In the due course of his practise, he has continued with his interests in clinical research (diabetes, renal dysfunction, resistant dermatitis, peripheral vascular disease and leading into innovative treatment measures). Since 2016, he has published 5 articles in the international journals.

E-mail: vinodtawar1943@gmail.com